Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133371) titled 'Adebrelimab combined with NALIRIFOX for neoadjuvant therapy of resectable pancreatic cancer' on Sept. 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University
Condition:
Resectable pancreatic cancer (RPC)
Intervention:
Arm A:Preoperative adebelimab + irinotecan liposome + oxaliplatin + 5-FU/LV
Arm B:Preoperative irinotecan liposome + oxaliplatin + 5-FU/LV
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2024-04-22
Target Sample Size: Arm A:60;Arm B:60;Arm C:60;
Countries of Recruitment:
Ch...